203 related articles for article (PubMed ID: 35360070)
21. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic marks in estrogen receptor alpha CpG island correlate with some reproductive risk factors in breast cancer.
Izadi P; Noruzinia M; Fereidooni F; Mostakhdemine Hosseini Z; Kamali F
Mol Biol Rep; 2014 Nov; 41(11):7607-12. PubMed ID: 25135164
[TBL] [Abstract][Full Text] [Related]
23. The emerging role of 27-hydroxycholesterol in cancer development and progression: An update.
Abdalkareem Jasim S; Kzar HH; Haider Hamad M; Ahmad I; Al-Gazally ME; Ziyadullaev S; Sivaraman R; Abed Jawad M; Thaeer Hammid A; Oudaha KH; Karampoor S; Mirzaei R
Int Immunopharmacol; 2022 Sep; 110():109074. PubMed ID: 35978522
[TBL] [Abstract][Full Text] [Related]
24. High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines.
Williams KE; Anderton DL; Lee MP; Pentecost BT; Arcaro KF
Epigenetics; 2014 Feb; 9(2):297-307. PubMed ID: 24225485
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
[TBL] [Abstract][Full Text] [Related]
27. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer.
Ung M; Ma X; Johnson KC; Christensen BC; Cheng C
Epigenetics; 2014 Apr; 9(4):523-32. PubMed ID: 24434785
[TBL] [Abstract][Full Text] [Related]
28. CpG methylation of the ERalpha and ERbeta genes in breast cancer.
Kim SJ; Kim TW; Lee SY; Park SJ; Kim HS; Chung KW; Lee ES; Kang HS
Int J Mol Med; 2004 Aug; 14(2):289-93. PubMed ID: 15254780
[TBL] [Abstract][Full Text] [Related]
29. A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes.
Bonneville R; Jin VX
Bioinformatics; 2013 Jan; 29(1):22-8. PubMed ID: 23104890
[TBL] [Abstract][Full Text] [Related]
30. 27-Hydroxycholesterol: the first identified endogenous SERM.
Umetani M; Shaul PW
Trends Endocrinol Metab; 2011 Apr; 22(4):130-5. PubMed ID: 21353593
[TBL] [Abstract][Full Text] [Related]
31. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD; Rivenbark AG; Jones WD; Coleman WB
Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
[TBL] [Abstract][Full Text] [Related]
32. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
33. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
34. The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer.
Munir MT; Ponce C; Powell CA; Tarafdar K; Yanagita T; Choudhury M; Gollahon LS; Rahman SM
J Steroid Biochem Mol Biol; 2018 Oct; 183():1-9. PubMed ID: 29733910
[TBL] [Abstract][Full Text] [Related]
35. The Cholesterol Metabolite 27HC Increases Secretion of Extracellular Vesicles Which Promote Breast Cancer Progression.
Baek AE; Krawczynska N; Das Gupta A; Dvoretskiy SV; You S; Park J; Deng YH; Sorrells JE; Smith BP; Ma L; Nelson AT; McDowell HB; Sprenger A; Henn MA; Madak-Erdogan Z; Kong H; Boppart SA; Boppart MD; Nelson ER
Endocrinology; 2021 Jul; 162(7):. PubMed ID: 33959755
[TBL] [Abstract][Full Text] [Related]
36. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.
Lewis-Wambi JS; Kim H; Curpan R; Grigg R; Sarker MA; Jordan VC
Mol Pharmacol; 2011 Oct; 80(4):610-20. PubMed ID: 21737572
[TBL] [Abstract][Full Text] [Related]
37. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
[TBL] [Abstract][Full Text] [Related]
38. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis.
Romagnolo DF; Papoutsis AJ; Laukaitis C; Selmin OI
BMC Cancer; 2015 Dec; 15():1026. PubMed ID: 26715507
[TBL] [Abstract][Full Text] [Related]
39. Evidence of pomegranate methanolic extract in antagonizing the endogenous SERM, 27-hydroxycholesterol.
Vini R; Juberiya AM; Sreeja S
IUBMB Life; 2016 Feb; 68(2):116-21. PubMed ID: 26756990
[TBL] [Abstract][Full Text] [Related]
40. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes.
Lappano R; Recchia AG; De Francesco EM; Angelone T; Cerra MC; Picard D; Maggiolini M
PLoS One; 2011 Jan; 6(1):e16631. PubMed ID: 21304949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
